Skip to content

5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trial

Photo

5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trial — PET-guided treatment de-escalation keeps HER2-positive breast cancer outcomes strong at five years

Used in

PET-guided treatment de-escalation keeps HER2-positive breast cancer outcomes strong at five years en